2013 – now |
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences/ Principal Investigator, Head of Applied Stem Cell Automation Research, Director for China Southern Territory for CAS equipment center |
2010 – 2013 |
DANAHER/ Product Development Manager, Biotherapeutics, Genetix, MolDev |
2009 – 2010 |
DANAHER/ Scientist – R&D Biology, Biotherapeutics, Genetix, Leica Microsystems |
2007 – 2009 |
Department of Cardiovascular Research, NHS, Royal Hallamshire Hospital/ Pre-clinical Research Fellow |
2005 – 2008 |
Medical School, Royal Hallamshire Hospital/ Ph.D, Immunology and Cell Biology |
1 Discovery of Cell Signalling mechanism and clinical use in degenerative disease
2 Instrumentation development for regenerative cell biology research and clinical application.
Dr Zhang joined GIBH in 2013 as a PI. He undertook several instrument development projects, and has developed the first instrument for hiPSC automated induction in the world. He have established the automation platform for cell culture, induction and differentiation, which will promote development of stem cell fundamental research and clinical application. Many patents have been applied base the automation system and Dr Zhang also have published several articles in relate research areas.
2. Songwei He, Jinlong Chen,……, Xiao Zhang, Yiping Guo, Duanqing Pei, Hui Zheng*. Sequential EMT-MET induces neuronal conversion through Sox2. Cell Discov. 2017 May; 3: 17017
3. Xiao Zhang, Gemma Montagut Pino, ……, Eva E. Qwarnstrom*. Distinct Control of MyD88 Adapter-dependent and Akt Kinase-regulated Responses by the Interleukin (IL)-1RI Co-receptor, TILRR. J Biol Chem. 2012 Apr ; 287(15): 12348–12352
4. Xiao Zhang, Freya Shephard, ……, Eva E. Qwarnstrom*. TILRR, a Novel IL-1RI Co-receptor, Potentiates MyD88. Recruitment to Control Ras-dependent Amplification of NF-κB. J Biol Chem. 2010 Mar ; 285(10): 7222–7232